Cargando…
Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG)
BACKGROUND: Survival benefit of adjuvant radiotherapy for locally advanced gastric cancer following gastrectomy plus D2 lymphadenectomy has always been controversial. Esophagogastric junction (EGJ) adenocarcinoma, which is usually classified as gastric cancer in East Asia, often has a higher locoreg...
Autores principales: | Shen, Jinwen, Zhu, Xiu, Du, Yian, Zhu, Yuan, Yu, Pengfei, Yang, Litao, Xu, Zhiyuan, Huang, Ling, Zhang, Yunli, Zhang, Yanqiang, Liu, Luying, Cheng, Xiangdong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556914/ https://www.ncbi.nlm.nih.gov/pubmed/34717717 http://dx.doi.org/10.1186/s13063-021-05617-7 |
Ejemplares similares
-
Nomogram for Predicting Risk of Esophagogastric Junction (EGJ) Resection During Laparoscopic Resection of Gastrointestinal Stromal Tumors in EGJ: A Retrospective Multicenter Study
por: Xu, Yuting, et al.
Publicado: (2021) -
The Impact of Magnetic Sphincter Augmentation (MSA) on Esophagogastric Junction (EGJ) and Esophageal Body Physiology and Manometric Characteristics
por: Ayazi, Shahin, et al.
Publicado: (2023) -
“Sandwich Therapy”—Immunotherapy Plus Concurrent Chemoradiotherapy for Advanced Esophagogastric Junction Carcinoma: Report of Two Cases and Literature Review
por: Wu, Lei, et al.
Publicado: (2022) -
Long-Term Efficacy of Neoadjuvant Concurrent Chemoradiotherapy for Potentially Resectable Advanced Siewert Type II and III Adenocarcinomas of the Esophagogastric Junction
por: Tian, Yuan, et al.
Publicado: (2021) -
Prognostic impact of sarcopenia in patients with locally advanced adenocarcinoma of the esophagogastric junction treated with neoadjuvant chemoradiotherapy
por: Ming, Jiao, et al.
Publicado: (2023)